A Urokinase Receptor-Bim Signaling Axis Emerges During EGFR Inhibitor Resistance in Mutant EGFR Glioblastoma

EGFR is the most common genetically altered oncogene in glioblastoma (GBM), but small molecule EGFR tyrosine kinase inhibitors (TKIs) have failed to yield durable clinical benefit. Here we show that in two novel model systems of acquired resistance to EGFR TKIs, elevated expression of urokinase plas...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Res
Auteurs principaux: Wykosky, Jill, Hu, Jingjing, Gomez, German G., Taylor, Tiffany, Villa, Genaro R., Pizzo, Donald, VandenBerg, Scott R., Thorne, Amy Haseley, Chen, Clark C., Mischel, Paul S., Gonias, Steven. L., Cavenee, Webster K., Furnari, Frank B.
Format: Artigo
Langue:Inglês
Publié: 2014
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4297573/
https://ncbi.nlm.nih.gov/pubmed/25432173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-2004
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires